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ORIGINAL ARTICLE
Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for
Treatment of Inﬂammatory Bowel Disease Complications
with Fibrosis
Laurence Gofﬁn, PhD,* Stefania Fagagnini, MD,† Alain Vicari, DVM, PhD,* Céline Mamie,†
Hassan Melhem, PhD,† Bruce Weder, MSc ETH Pharm Sc,† Christian Lutz, MD,† Silvia Lang,†
Michael Scharl, MD,† Gerhard Rogler, MD, PhD,† Yolande Chvatchko, PhD,* and Martin Hausmann, PhD†
Background: Despite medical treatments or surgical options, more than one-third of patients with Crohn’s disease suffer from recurring ﬁstulae. Matrix
metalloprotease 9 (MMP-9), a type IV collagenase that cleaves components of the extracellular matrix leading to tissue remodeling, is upregulated in
crypt abscesses and around ﬁstulae suggesting an important role for this enzyme in ﬁstula formation. Our aims were (1) to correlate serum levels of
MMP-9 degradation products in patients with CD with the presence of ﬁstulae and (2) to investigate the impact of selective MMP-9 inhibition in a mouse
model of intestinal ﬁbrosis.
Methods: Serum MMP-9 degradation products were quantiﬁed in subjects affected with nonstricturing and nonpenetrating CD (n ¼ 50), stricturing CD
(n ¼ 41), penetrating CD (n ¼ 22), CD with perianal ﬁstula (n ¼ 29), and healthy controls (n ¼ 10). Therapeutic efﬁcacy of anti-MMP-9 monoclonal
antibodies was assessed in a heterotopic xenograft model of intestinal ﬁbrosis.
Results: C3M, an MMP-9 degradation product of collagen III, demonstrated the highest serum levels in patients with penetrating CD and differentiated
penetrating CD from other CD subgroups and healthy controls, P ¼ 0.0005. Anti-MMP-9 treatments reduced collagen deposition and hydroxyproline
content in day-14 intestinal grafts indicating reduced ﬁbrosis.
Conclusions: The serologic biomarker C3M can discriminate penetrating CD from other CD subgroups and could serve as marker for the development
of penetrating CD. Anti-MMP-9 antibody has therapeutic potential to prevent intestinal ﬁbrosis in CD complications.
(Inﬂamm Bowel Dis 2016;22:2041–2057)
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C rohn’s disease (CD) is a chronic immune-mediated inﬂam-matory condition of the gastrointestinal tract. Initially, the
majority of patients develop a purely inﬂammatory presentation of
disease (Montreal Class B1 inﬂammatory phenotype). However,
some patients eventually develop intestinal ﬁbrosis leading to the
development of severe complications, such as intestinal strictures
(Montreal Class B2 ﬁbrostenotic phenotype) and ﬁstulae (Montreal
B3 penetrating phenotype).1,2 The development of ﬁstulae in the
course of the disease is a common complication. Fistula formation
has been reported in 17% to 50% of patients with CD in population-
based studies and about 35% of patients with CD suffer from at
least one ﬁstula during the course of their disease.3 A ﬁstula is an
abnormal channel or passageway connecting 2 parts of the bowel or
the bowel to the vagina, bladder, or skin. The occurrence of ﬁstulae
results in considerable morbidity, including permanent sphincter
and perianal tissue destruction as well as professional and personal
disabilities. Despite current medical options, including antibiotics,
immunosuppressants (such as azathioprine or cyclosporine), anti-
TNF antibodies and surgery, permanent closure of ﬁstula can only
be achieved in about one-third of patients with CD4 and a further
third suffer from recurring ﬁstulae,5 indicating that new and more
effective therapeutic approaches are urgently needed for patients
suffering from CD-associated ﬁstulae. CD-associated ﬁstulae orig-
inate from an epithelial defect that may be caused by ongoing
inﬂammation. Having undergone epithelial-to-mesenchymal transi-
tion (EMT), intestinal epithelial cells penetrate into deeper layers of
the mucosa and the gut wall, causing localized tissue damage and
formation of a tube-like structure that connects the gastrointestinal
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tract to other organs or the skin. EMT enhances the activation of
matrix remodeling enzymes, such as matrix metalloproteinases
MMP-3 and MMP-9, causing further tissue damage and inﬂamma-
tion.6,7 MMP-9 (also known as gelatinase B) is a zinc-dependent
endopeptidase responsible for the degradation of gelatin, denatured
collagens, and basement membrane.8 It is involved in many devel-
opmental processes, including angiogenesis, wound healing, and
extracellular matrix (ECM) degradation. Additional roles for
MMP-9 have recently emerged, including its ability to regulate cell
migration, invasion, cell signaling, and EMT in multiple tissues.9–11
MMP-9 is the most abundantly expressed protease in inﬂamed CD
tissues, and its upregulation leads to an increase in net MMP pro-
teolytic activity.12–14 In biopsies from CD mucosa, MMP-9 was
found as monomers and oligomers, as latent (pro-) and mature
forms, and complexed with other molecules. Pro-MMP-9 and
MMP-9 complexed to TIMP-1 are inactive, whereas MMP-9 asso-
ciated with neutrophil gelatinase–associated lipocalin (NGAL) is
enzymatically active.15 Both inactive and active MMP-9 are ex-
pressed surrounding CD ﬁstulae. Moreover, increased mRNA and
protein levels, of MMP-9 and of its physiological activator MMP-3,
were found in granulocytes, mononuclear cells, and ﬁbroblasts,13
suggesting an important role for these enzymes in ﬁstula formation.
Serum and urinary levels of MMP-9 correlate with disease
activity in CD and ulcerative colitis (UC).16,17 MMP-3 and
MMP-9 serum levels were suggested to be useful markers of
disease activity in children with UC18 and in inﬂammatory bowel
disease (IBD).19 Circulating levels of NGAL or the NGAL/MMP-
9 complex have recently been described as a potential biomarker
for mucosal healing in UC treated with inﬂiximab, with reduced
serum levels being predictive of mucosal healing.20,21 These ﬂuc-
tuating circulating levels of MMP-9 reﬂect the changes of MMP-9
concentration in the organ, but not of its activity. Therefore,
a method allowing the quantiﬁcation of MMP-9 activity in serum
mirroring its activity in tissue would aid in the diagnosis, in the
monitoring of the course of disease, and in the evaluation of the
effectiveness of IBD treatment.
The involvement of MMPs for the development of CD is
highlighted by the fact that in the mouse dextran sodium sulfate
(DSS)-induced colitis model, targeted deletion ofMmp9 has a pro-
tective effect,22,23 whereas mice overexpressing MMP-9 in the
intestinal epithelium develop more severe colitis when compared
with wild-type animals.24 At present, no animal model that repro-
duces the unique histological features associated with CD intes-
tinal ﬁstulae exists, but there are several models that address
speciﬁc aspects of the pathogenesis of CD ﬁstulae. One of these,
the heterotopic transplant mouse model developed recently could
be used to investigate intestinal ﬁbrosis.25
In this study, we show that, in patients with penetrating CD,
increased MMP-9 expression associated with ﬁstula tracks is
reﬂected by elevated serum levels of C3M, an MMP-9 degrada-
tion type III collagen product. We also report the efﬁcacy of 2
independent selective anti-MMP-9 monoclonal antibodies in the
heterotopic transplant mouse model of intestinal ﬁbrosis. Collec-
tively, these data indicate that MMP-9 plays a key role in the
modulation of intestinal ﬁbrosis and suggest that selective MMP-9
inhibition is a promising therapeutic strategy for the treatment of
penetrating CD.
MATERIALS AND METHODS
Tissue and Serum Samples from Patients with
IBD and Healthy Controls
Perianal ﬁstula specimens from patients were prospectively
collected for immunohistochemistry (IHC) from men and women
with and without CD. We investigated 5 ﬁstulae in formalin-ﬁxed
tissue samples from 5 patients with perianal ﬁstulae as indicated
in Table 1. Tissue samples were surgically resected and immedi-
ately transferred to 4% formalin and stored at 48C until further
analysis. Written informed consent was obtained before specimen
collection, and the studies were approved by the local ethics
committee.
Ethical Considerations
The experimental protocol for animals was approved by
the local Animal Care Committee of the University of Zurich
(registration number ZH183/2014).
Written informed consent was obtained before human
specimen collection and studies were approved by the local
ethics committee. The cohort study is supported by the Swiss
National Science Foundation and approved by the local
ethical committees (IRB approval number: EK-1316, approved
TABLE 1. Characteristics of Patients with Perianal Fistulae
Patients F20 F21 F22 F23 F24
Comment Secondary ﬁstula Secondary ﬁstula, drainage Gluteal ﬁstula system Intersphincteric ﬁstula Fistula with abscess
Gender Female Male Male Male Female
Age (yrs) at time
of sampling
25 72 59 41 46
Fistula since, yrs 1–3 ,1 .3 ,1 ,1
Diagnosis CD non-CD CD non-CD non-CD
Medication Yes No No No No
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on February 5, 2007 by the Cantonal Ethics Committee of the
Canton Zürich, Switzerland).
Serum samples were obtained from HC between 29 and 49
years of age, with no history of IBD or treatment for such disease.
All subjects felt healthy and had no reported pain or symptoms of
any disease, and all gave their written informed consent. Serum
samples from patients suffering from CD were obtained from the
Swiss Inﬂammatory Bowel Disease Cohort Study. All patients had
an established diagnosis of CD.26 Patients had received standard
care, including physical therapy, and treatment with antibiotics, 5-
aminosalicylates, corticosteroids, azathioprine, 6-mercaptopurine,
methotrexate, cyclosporine, and/or TNF inhibitors such as
inﬂiximab (Remicade; Centocor), adalimumab (Humira; AbbVie),
and certolizumab pegol (Cimzia; UCB). Patients were classiﬁed
into subgroups according to the Montreal classiﬁcation,2 as indi-
cated in Table 2.
Biomarker Assays
Several neoepitope fragments resulting from ECM synthe-
sis and degradation were assessed by solid phase competitive
enzyme linked immunosorbent assays (ELISAs) developed by
Nordic Bioscience Laboratory. A selection of 5 MMP-9-speciﬁc
degradation products from collagen and ECM proteins were
quantiﬁed in serum samples from healthy controls (HC) and from
patients with penetrating CD (group B3 of CD), using competitive
ELISAs. The C3M ELISA measures type III collagen fragments27
and the BGM ELISA measures biglycan fragments, both gener-
ated by MMP-9 in connective tissues.28 The C1M ELISA meas-
ures type I collagen fragments generated by MMP-2, MMP-9, and
MMP-13 in connective tissues.29 The C6M ELISA measures type
VI collagen fragments generated by MMP-2 and MMP-9 in
muscles30,31 and the LAM ELISA measures laminin fragments
generated by MMP-2 and MMP-9 in basement membranes.
C3M fragment was measured in serum samples from HC and
from all groups of patients with CD.
Anti-MMP-9 Antibody Production
Anti-MMP-9 binders have been isolated using single-chain
fragment variable (scFv) phage display selection and screening
technology. The Dübel HAL7 (Lambda) scFv library was ob-
tained from the Mab Factory company (Braunschweig, Germany).
The selection of phages that bind the target was performed using
biotinylated recombinant human or mouse MMP-9 proteins, im-
mobilized on streptavidin paramagnetic beads. These recombinant
TABLE 2. Characteristics of Patients with CD and of HC
Baseline Characteristics
CD B1 (Nonstricturing and
Nonpenetrating CD) (n ¼ 50)
CD B2 (Stricturing
CD) (n ¼ 41)
CD B3 (Penetrating
CD) (n ¼ 22)
CD B3p (CD with
Perianal Fistula) (n ¼ 29) HC (n ¼ 10)
Gender
Female, (%) 22 (44) 25 (61) 8 (36) 19 (65) 6 (60)
Male, (%) 28 (56) 16 (39) 14 (64) 10 (35) 4 (40)
Age, mean years (range) 40.36 (17–71) 47.51 (23–79) 36.55 (16–63) 39.43 (22–64) 37.67 (29–49)
Duration of disease at
sampling, median year,
(range)
8 (0–34) 15 (0–35) 13 (1–37) 8 (2–38) NA
Clinical disease activity at
sampling
Active, (%) 17 (34) 12 (30) 8 (36) 9 (31) NA
Quiescent, (%) 33 (66) 29 (70) 14 (64) 20 (69) NA
Abscess at time of sampling 0 0 15 2 NA
Stenosis at the time of
sampling
0 29 11 7 NA
History of intestinal surgery 16 34 15 9 NA
Medication
5-aminosalicylates 12 12 7 NA
Steroid 11 14 8 NA
Azathioprine/6
mercaptopurine
18 22 5 7 NA
Methotrexate 5 1 3 NA
Anti-TNFa 13 11 5 10 NA
Antibiotics 1 3 2 NA
Cyclosporine 2 NA
Immunosuppressor + anti-
TNFa (Combo therapy)
9 NA
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proteins were generated by cloning the full-length cDNA of
human (NM_004994) or mouse (NM_013599) Mmp9 into the
pBluescript II vector and by transiently transfecting it into
HEK-293 cells (ATCC, Molsheim, France). Binders to MMP-9
proteins (and not to MMP-2) were then screened for neutralizing
activity in a cell-free enzymatic activity assay, using either full-
length MMP-9 or MMP-9 catalytic domain and a ﬂuorogenic
substrate (porcine DQ-Gelatin from Invitrogen, Ref D12054).
Optimization of selected hit candidates was performed, by afﬁnity
maturation conducted through lambda light chain shufﬂing fol-
lowed by germlining and by CDR mutations. After these optimi-
zation steps, the fully human anti-human MMP-9 antibody
CALY-001 was selected and expressed as human IgG4/kappa
antibody in transiently transfected Chinese hamster ovary cells.
A comparator antibody, the AB0046-h4 mouse monoclonal anti-
body against mouse MMP-9, was generated using sequences of
the variable regions of AB0046 antibody described in patent
WO2012/027721A2. AB-0046 is a selective and potent allosteric
antibody inhibitor of mouse MMP-9, which was shown to reduce
disease severity in a DSS-induced mouse model of UC.32 The
construct was subcloned and expressed as human IgG4/kappa
antibody in transiently transfected CHO cells. Antibodies were
puriﬁed using Protein A agarose, MAbSelect SURE (Sigma
Aldrich, Ref 17-5438-01) and resuspended in phosphate-
buffered saline, pH 7.4. Production batches exhibit protein purity,
estimated by SDS-PAGE resolution, greater than 95% and endo-
toxin levels, quantiﬁed by a commercial kit, lower than 1 EU/mL.
MMP-9 Enzymatic Assays
Gelatinase activity of natural forms of MMP-9 was assessed
using a cell-free enzymatic assay. Brieﬂy, a ﬂat bottom nonbinding
96-well black plate was ﬁlled with monomeric, dimeric, or NGAL-
bound form of MMP-9 puriﬁed from human neutrophils (0.24 ng/mL
ﬁnal) and with the catalytic domain of recombinant human MMP-3
(Calbiochem, Ref 444217, 0.90 ng/mL ﬁnal). After an overnight
activation at RT, serial dilutions of CALY-001 and anti-MMP-9
antibody were added and incubated for 1 hour at RT. The enzymatic
reaction was initiated by addition of the porcine ﬂuorogenic substrate
DQ-Gelatin, and the incubation was performed at RT in the dark for
2 hours. The intensity of the ﬂuorometric reaction was measured
by reading light emission at 520 nm on excitation at 485 nm
(Ex485/Em520). The resulting ﬂuorescence values are proportional
to the remaining enzymatic activity in each well. Data were corrected
by withdrawal of their respective negative (no enzyme) control wells
and plotted against antibody concentrations. A 4-parameter curve ﬁt
was used with Prism software (GraphPad, v6.0) to determine the half
maximal inhibitory concentration (IC50) of the CALY-001 antibody
against each MMP-9 species tested.
For testing the selectivity of the CALY-001 antibody for
MMP-9 versus other MMP enzymes, a commercial kit (MMP
Inhibitor proﬁling kit, Enzo, Ref BML-AK308) was used following
the manufacturer’s instructions. Brieﬂy, a ﬂat bottom nonbinding 96-
well black plate was ﬁlled with the catalytic domain of each human
MMP available in the kit. An optimal dilution of CALY-001
antibody (100 nM ﬁnal) was then added and incubated for 1 hour
at RT. A control reaction, replacing CALY-001 antibody by the
small molecule MMP inhibitor N-Isobutyl-N-(4-methoxy-phenyl
sulfonyl) glycyl hydroxamic acid (NNGH, 1.3 mM ﬁnal), was also
included in the study. Enzymatic activity was revealed on the addi-
tion of OmniMMP RED substrate (Enzo, Ref BML-P277-0100) and
measured by reading light emission at 590 nm on excitation at 540
nm (Ex540/Em590). The resulting ﬂuorescent values are propor-
tional to the remaining enzymatic activity in each well. Results are
expressed as mean percentages of remaining activity (%), with 100%
set for reaction without antibody.
The kinetics and afﬁnity of antibody binding to MMP-9 were
determined by surface plasmon resonance using a BIAcore T200.
Brieﬂy, antibodies were captured onto anti-human Fc-coated
surface and the target protein, pro-MMP-9 or MMP-3-activated
MMP-9, was dose-titrated from 4.7 to 150 nM in a 2-fold step
dilution. Analysis of the resulting sensograms provides values of
apparent dissociation constant (KD).
Heterotopic Intestinal Transplant Model
Female B6-Tg(UBC-GFP)30Scha/J donor mice (GFP-Tg)33
weighing 20 g were bred at the University of Zurich. Female 10-
week-old C57BL/6J-Crl1 mice (C57BL/6) were obtained from
Charles River. The animals received standard laboratory mouse food
and water ad libitum. They were housed under speciﬁc pathogen-
free conditions in individually ventilated cages. The experimental
protocol was approved by the local Animal Care Committee of the
University of Zurich (registration number ZH183/2014).
The heterotopic mouse intestinal transplant model has
been described in detail.25 In short, donor small bowel resections
were extracted and transplanted subcutaneously into the neck of
recipient animals. All procedures were performed using a sterile
nontouch technique. Donor mice were euthanized and after an
initial anterior midline incision, the abdomen was opened com-
pletely to avoid contamination of the inner organs with hair. The
small bowel was then exposed and carefully unfolded by cutting
mesentery where necessary. From the small bowel proximal to
the caecum a segment of 6 cm was excised. The resection was
then ﬂushed with 5 mL of 0.9% NaCl to remove stool and
divided into 6 equal 10-mm parts. Resections were kept moist
with 0.9% NaCl solution, whereas the recipient animals were
prepared for transplantation. Recipient animals were anesthe-
tized with isoﬂurane and ocular lubricant was applied (Vitamin
A Blache Augensalbe 5 g, Ref 109778). A small area of the back
was shaved to avoid contamination with hair. Two subcutaneous
pouches were prepared through a small incision perpendicular to
the body axis on either side of the neck. A small bowel resection
was implanted into each of the subcutaneous pockets, and the
skin was closed using vicryl 5-0 stiches or a 3M Precise Vista
skin stapler. A single dose of cefazolin (Kefzol, 1g diluted in
2.5 mL distilled water; Teva Pharma AG, Basel, Switzerland)
was applied intraperitoneally as prophylaxis against infection.
Monoclonal anti-MMP-9 antibodies (CALY-001 and
AB-0046-h4) and the isotype control antibody were administered
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intraperitoneally at 30 mg/kg on day 5, 8, and 11 after
transplantation. At study termination 14 days after transplanta-
tion, recipient mice were euthanized and intestinal grafts were
explanted. Each explanted graft was divided into 3 equal
segments. One segment was ﬁxed in 4% formalin and prepared
for histopathological assessment. The other segments were snap
frozen in liquid nitrogen and stored at 2808C until RNA and
protein extractions were performed. The sections were examined
with the Imager Z2 microscope (Zeiss) and the software Axio-
Vision (Zeiss). Sirius Red stained slides were analyzed under
bright ﬁeld using a polarization ﬁlter. Under polarized light
Sirius Red–stained collagen assumes a palette of colors ranging
from green to red as a sign for increasing maturation of the
ﬁbrotic process. Collagen layer thickness was measured by an
investigator blinded to study groups. Means of collagen layer
thickness were calculated from at least 8 places in representative
areas at 10-fold magniﬁcation.
IHC and Immunoﬂuorescence
For the detection of MMP-9 by IHC, heat-mediated
antigen retrieval was performed using Tris-HCl/EDTA buffer
pH 9 (Ventana, Ref 950224). MMP-9 was stained with a rabbit
monoclonal antibody from Abcam (Ref ab137867, dilution
1:800). An HRP-polymer conjugated anti-rabbit IgG was used
as secondary antibody. EnVision HRP stain system (labeled
polymer anti-rabbit, Dako) was used for visualization. All
sections were counterstained with hematoxylin.
For the detection of human IgGs by IHC, protease 1 pre-
treatment was performed (Ventana, 12 minute). Human IgGs
were stained with a polyclonal rabbit anti-human antibody from
Dako (Ref A0423, dilution 1:15,000). Ultra Map anti-rabbit
antibody (Ventana) was used as secondary antibody (immun-
stainer, Ventana Discovery Ultra Stainer). ChromoMap DAB kit
(Ventana) was used for visualization. IHC of sections isolated
from human tonsil was the positive control, and IHC in the
absence of primary antibody of sections from freshly isolated
small bowel was the negative control.
For the detection of E-cadherin or a-smooth muscle actin
(SMA) by immunoﬂuorescence (IF), heat-mediated antigen
retrieval was performed using either citrate buffer pH 9.0 (Dako,
Ref S2367) or citrate buffer pH 6.0 (Dako, Ref S1699), respec-
tively. E-cadherin was tagged with a rabbit monoclonal antibody
from Cell Signaling (Ref 3195, dilution 1:200). Alpha-SMA was
tagged with a rabbit polyclonal antibody from Abcam (Ref
ab5694, dilution 1:200). An Alexa Fluor 647 dye-coupled anti-
rabbit IgG (Life Technologies, Ref A21244) was used as secondary
antibody. All sections were counterstained with 40,6-diamidino-2-
phenylindole (DAPI). The sections were examined with the Imager
TCS SP5 (Leica) and the software LAS AF (Leica).
Zymography
The activity of MMP-9 was measured by zymography in
homogenates of intestinal grafts as previously described.34
Brieﬂy, intestinal grafts were homogenized on ice in lysis buffer
(25 mM Tris-HCl pH 7.5, 100 mM NaCl, and 1% IGEPAL),
containing protease inhibitors (10 mg/mL aprotinin, 2 mg/mL
leupetin, 4 mM benzamidine), using disposable pellet Pestles
(Sigma, Ref Z359947). The total protein concentration of the
resulting homogenates was determined by Bradford assay. Equiv-
alent protein amounts (10 mg) of each homogenate were mixed
with electrophoresis loading buffer x2 (1:1; vol:vol) and resolved
by zymography using Novex 10% Zymogram Protein Gels (Ref
EC61752BOX), as described in the manufacturer’s instructions.
The gelatinase activities appear as transparent bands against the
background of Coomassie brilliant blue-stained gelatin. Pro-
MMP-9 and MMP-9 species were identiﬁed by comparison of
their migration to that of puriﬁed pro-MMP-9 and MMP-9 re-
combinant proteins. Pictures of zymogram gels were acquired
using the Azure C200 gel imaging system and semiquantitative
analysis of total MMP-9 amounts was performed using ImageJ
software (version 1.49). Results are expressed as arbitrary units.
Hydroxyproline Determination
Hydroxyproline content was quantitated from freshly
isolated small bowel and grafts using the chloramine T colori-
metric method35 with minor modiﬁcations.36 In brief, tissues (20–
50 mg) were weighed and hydrolyzed in 500 mL of 6 N HCl at
1008C for 24 hours. The hydrolysate was ﬁltered using a 0.2 mm
syringe ﬁlter. Samples (20–50 mL) were dried in a vacuum evap-
orator. Dried samples were incubated with 500 mL of chloramine
T solution (1 part 7% chloramine T and 4 parts citrate/acetate
buffer [pH 6.0, 695 mM sodium acetate, 128 mM trisodium cit-
rate_2H2O, 29 mM citric acid, and 38.5% isopropanol]) at room
temperature for 25 minutes. Five hundred microliter of Ehrlich’s
solution (1.4 M dimethylaminobenzaldehyde, 20% perchloric acid
and 67% isopropanol) was then added, and samples were incu-
bated at 658C for 20 minutes for chromophore formation. After
cooling, the absorbance was read at 561 nm. Hydroxyproline
concentration was calculated from a standard curve prepared with
high-purity hydroxyproline. The results were expressed as micro-
grams of hydroxyproline per gram of tissue.
ELISA for MMP-9 Activity Assay in Serum
Quantiﬁcation of MMP-9 activity in homogenates of
intestinal grafts was performed by ELISA, using the mouse
MMP-9 activity assay kit from QuickZyme (Ref QZBMMP9m).
Brieﬂy, equivalent amounts of total proteins of each graft
homogenate were dispensed onto 96-well plate, precoated with
anti-mMMP9 antibody. After overnight incubation at 48C, wells
were washed with phosphate-buffered saline/0.05% Tween 20,
and the detection reagent (peptide substrate of MMP-9) pro-
vided in the kit was added to quantify active mature MMP-9.
Release of chromogenic cleaved peptide was measured at 405
nm using an ELISA plate reader. A calibration curve derived
from results obtained with known amounts of mouse MMP-9
standards was used to determine amounts of active MMP-9 in
tested samples. The lower limit of quantiﬁcation of this assay
is 1 pg/mL.
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ELISA for TGFb Protein Quantiﬁcation
Quantiﬁcation of TGFb in homogenates of intestinal grafts
was performed by ELISA, using the mouse TGF-b1 Duoset kit
(R&D Systems, Ref DY1679). The protocol is similar to that used
for monitoring of MMP-9 activity, with direct reading of total
TGFb and speciﬁc reading of active TGFb species after the acidic
activation of the samples. The quantiﬁcation range of this assay is
31.2 to 2000 pg/mL.
TaqMan Gene Expression Assays
Genes and names of the probes used to quantify their
expression are the followings: Mmp9; Mm00442991_m1, Timp1;
Mm00441818_m1, transforming growth factor beta 1 (Tgfb1);
Mm01178820_m1 and Gapdh; 4352339E. The relative cDNA
concentration for the genes of interest was calculated using the
ddCt-method.
Statistical Analysis
Data were analyzed and visualized using Prism software
(GraphPad, v6.0). Statistical analysis was performed using one-
way analysis of variance with Dunnett’s Multiple Comparison
posttest or unpaired t test with Welch’s correction for pairwise
analysis. Statistical analysis for quantiﬁcation of gene expression
and MMP-9 activity levels was assessed by Kruskal–Wallis
analysis.
RESULTS
MMP-9 is Strongly Expressed in Tissue
Alongside Fistula Tracts
Histological analysis of colonic tissue specimens showed
a strong staining for MMP-9 in the tissue surrounding the ﬁstula
tracts of patients with perianal ﬁstulae (Fig. 1A, B). Staining was
most prominent in squamous cell epithelia associated with the
distal part of the ﬁstula tract. Marked staining in the distal part
was clearly deﬁned to an unstained proximal part. In addition, we
found MMP-9 staining in epithelial cells of deformed crypts
directly next to the ﬁstula tracts (Fig. 1C) and in inﬂammatory,
mainly lymphocytic, inﬁltrates adjacent to the ﬁstula tracts (Fig.
1D) compared with a weaker staining at sites distant from ﬁstula.
These ﬁndings demonstrate that MMP-9 is expressed in squamous
cell layers, epithelial cells of deformed crypts alongside and next
to ﬁstulae, as well as in inﬂammatory inﬁltrates, suggesting an
involvement of MMP-9 in the pathogenesis of colon ﬁstulae.
C3M, an MMP-9-generated Fragment of Type
III Collagen, is a Potential Biomarker of
Penetrating CD
We hypothesized that the elevated MMP-9 expression
observed in intestinal biopsies from patients with CD with ﬁstula
(penetrating CD, B3 group) was associated with increased local
MMP-9 enzymatic activity, leading to the release of MMP-9-
generated protein-degradation products, locally and into the
circulation. To investigate whether certain MMP-9-generated
protein fragments could be biomarkers of penetrating CD, and/
or subgroups of patients with CD, we selected 5 peptides released
either by MMP-9 (C3M and BGM), MMP-2/9 (C6M and LAM),
or MMP-2/9/13 (C1M), mediated proteolysis, and compared their
levels in serum from B3 patients to those in serum from HC.
Characteristics of these subjects are reported in Table 2. C3M
(MMP-9-generated type III collagen fragment) was the only neo-
peptide that demonstrated signiﬁcant difference between the 2
groups, with a 1.9-fold serum level increase in CD B3 patients
compared with levels observed in HC (P ¼ 0.0005, Table 3). In
FIGURE 1. MMP-9 expression in intestinal mucosa of patients with perianal ﬁstulae. Surgically resected colonic tissue specimens were im-
munohistochemically stained for MMP-9 (brown staining). (A and B) MMP-9 alongside ﬁstula tract (merged ·5 magniﬁcation). MMP-9 staining (C)
in epithelial cells of deformed crypts (arrows) and (D) in inﬂammatory inﬁltrates adjacent to the ﬁstula tract (arrows). Images representative of all
investigated samples (n ¼ 5). Scales as indicated. Dotted line, ﬁstula tract; f, ﬁstula lumen; i, intestinal lumen.
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addition, although the difference in serum levels of BGM, bigly-
can fragment generated by MMP-9, between CD B3 patients and
HC failed to reach statistical signiﬁcance, we observed a good
correlation between serum levels of C3M and BGM (r2 ¼ 0.8038,
P , 0.0001) in CD B3 patients (data not shown).
We next focused on C3M peptide and compared its serum
levels in patients with nonstricturing and nonpenetrating CD (B1
group), stricturing CD (B2 group), and perianal ﬁstula CD (B3p
group) with levels in serum from HC. None of the other CD patient
groups showed a signiﬁcant difference in the mean value of C3M
serum levels when compared with HC as shown in Figure 2 and
Table 4. Interestingly, the mean value of serum levels of C3M was
not increased in the CD B3p patients compared with levels
observed in HC. Although CD B3p patients have perianal ﬁstulae,
they have less severe disease compared with B3 patients who have
abdominal ﬁstulae with abscesses, indicating that C3M could also
be a biomarker of penetrating CD severity. The mean value of C3M
levels in CD B3 patients was statistically different when compared
with B1 (P¼ 0.0056), B2 (P¼ 0.0003), and B3p CD (P¼ 0.0004)
subgroups, indicating that increased C3M serum levels are potential
biomarkers of penetrating CD.
CALY-001 Monoclonal Antibody is a Potent
and Selective Inhibitor of Human and
Mouse MMP-9
MMP-9-speciﬁc fully human monoclonal antibodies were
generated by phage display technology using recombinant human
MMP-9 proteins. Single-chain variable fragments (scFv) were
selected by in vitro screening for target binding and inhibition of
substrate proteolysis. After reformatting clones of interest to
human IgG4, candidates were tested for potency, efﬁcacy, species
speciﬁcity, and selectivity versus other MMP family members.
The selection process yielded CALY-001, which inhibits human
and mouse MMP-9-mediated cleavage of the physiologically
relevant substrate gelatin (partially denatured collagen) with
similar potency and efﬁcacy: IC50 ¼ 0.976 0.16 nM for recombi-
nant human MMP-9 and IC50 ¼ 1.27 6 0.2 nM for recombinant
mouse MMP-9, with 100% efﬁcacy. CALY-001 exhibits binding
to activated MMP-9, with KD ¼ 12 nM, but not to pro-MMP-9,
with KD . 15 mM (data not shown). CALY-001 showed greater
than 100-fold selectivity for human MMP-9 versus 8 other tested
MMP family members including MMP-2, which is highly homol-
ogous to MMP-9 (Fig. 3A). Cell-free enzymatic assays using
either recombinant pro-MMP-9 or APMA-activated MMP-9
FIGURE 2. Serum levels of neopeptide C3M in subsets of patients with
CD and HC. Nonstricturing and nonpenetrating CD (B1; open triangle;
n ¼ 50), stricturing CD (B2; closed circle; n ¼ 41), penetrating CD (B3;
open circle; n ¼ 22), CD with perianal ﬁstula (B3p; closed square; n ¼
29), and HC (closed triangle; n ¼ 10). Statistical analysis was performed
using one-way analysis of variance with Dunnett’s multiple compari-
son posttest to reveal any signiﬁcant difference between the groups.
ns, not signiﬁcant.
TABLE 3. Difference in Serum Biomarkers in Patients with Penetrating (Montreal B3) CD and HC
Enzyme
Involved Neopeptide
HC CD B3 Patients
P, B3
Versus HCN
Mean 6 SD
(ng/mL)
Lower and Upper
95% CI of Mean N
Mean 6 SD
(ng/mL)
Lower and Upper
95% CI of Mean
MMP-9 C3M 10 12.27 6 2.11 10.75–13.78 22 23.29 6 12.50 17.74–28.83 0.0005
MMP-9 BGM 10 19.67 6 6.71 14.87–24.57 22 29.41 6 24.06 18.74–40.08 ns
MMP-2/9 C6M 10 17.67 6 6.27 13.18–22.16 20 27.75 6 24.30 16.37–39.12 ns
MMP-2/9 LAM 10 24.25 6 32.84 0.758–47.74 20 9.02 6 5.66 6.37–11.67 ns
MMP-2/9/13 C1M 10 43.72 6 16.13 32.19–55.26 20 91.4 6 105.3 42.1–140.7 ns
Statistical analysis was performed using unpaired t test with Welch’s correction. Twenty of 22 serum samples from the B3 group were tested for C6M, LAM, and C1M because of limited
serum sample volume.
ns, not signiﬁcant.
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revealed that CALY-001 is a pure inhibitor of enzymatic activity
behaving as noncompetitive inhibitor, as the IC50 values generated
against the enzyme activity on a peptide substrate were not substan-
tially affected by substrate concentrations ranging from 1 to 7.5 mM
(data not shown). CALY-001 inhibition of natural forms of MMP-9
was evaluated using MMP-9 monomers, dimers, and NGAL/MMP-9
complexes puriﬁed from human neutrophils. As shown in Figure 3B,
CALY-001 efﬁciently inhibited cleavage of DQ-gelatin by MMP-9
monomers with an IC50 ¼ 1.37 nM, MMP-9 dimers with an IC50 ¼
0.45 nM, and NGAL/MMP-9 with an IC50 ¼ 1.77 nM.
CALY-001 Anti-MMP-9 Antibody Decreases
Intestinal Fibrosis in a Mouse Model
Effect of MMP-9 inhibition was assessed in the heterotopic
transplant mouse model of intestinal ﬁbrosis by starting treatment
with anti-MMP-9 antibodies CALY-001 or AB-0046-h4 5 days
after transplantation. In this study, we have used AB-0046-h4 as
a comparator. Body weight remained unchanged in animals
treated with anti-MMP-9 antibody, CALY-001, or AB-0046-h4,
and in animals treated with isotype control (data not shown).
Grafts were explanted 14 days after transplantation, and collagen
production and deposition were analyzed on Sirius Red staining
under transmission light and under polarizing light in 2 indepen-
dent experiments, and compared with freshly isolated intestinal
resections. Results of experiment 1 are shown in Figure 4. Freshly
isolated intestinal resections were characterized by an open lumen
and distinctive epithelial crypts (Fig. 4A, B). In the isotype con-
trol–treated group, at day 14 after transplantation, the lumen of
intestinal grafts was fully obstructed by granular tissue and
ﬁbrotic material (Fig. 4D, E). In the anti-MMP-9 antibody-treated
groups, the lumen of the intestinal grafts was only partially ob-
structed, and some crypt structures were still present. Freshly
isolated intestinal samples showed a thin collagen layer adjacent
to the submucosa (Fig. 4B, C). The collagen layer was much
thicker in grafts harvested from the isotype control–treated group:
a massive accumulation of collagen was observed, spreading from
the submucosa to the occluded lumen (Fig. 4E, F). In contrast, in
grafts harvested from anti-MMP-9 antibody-treated mice, the col-
lagen layer was only slightly thicker than that observed in freshly
isolated intestinal samples (Fig. 4H, I, L, M). Freshly isolated
intestinal samples showed long-chained collagen (red stain) bor-
dering the submucosa (Fig. 4C). In grafts from isotype control–
treated mice, increased short-chain collagen (green stain) was
observed in the submucosa and in the luminal occlusion as a sign
of an ongoing ﬁbrotic process (Fig. 4F). In contrast, long-chain
collagen (red stain) was associated with a thinner collagen layer in
grafts from mice treated with anti-MMP-9 antibody CALY-001
and AB-0046-h4 as a sign of lower accumulation of newly
FIGURE 3. Characterization of MMP selectivity of CALY-001. A, Neutralization of catalytic domain of various human MMPs by MMPs broad inhibitor
(NNGH), by isotype control antibody, or by CALY-001 anti-MMP-9 antibody. Remaining activities were normalized to conditions where no inhibition
was applied. B, Neutralization of natural forms of MMP-9 by CALY-001. CALY-001-mediated inhibition of DQ-gelatin degradation by MMP-3-activated
human monomeric MMP-9 (triangles), dimeric MMP-9 (circles), and NGAL-MMP-9 complex (squares) derived from human neutrophils was evaluated
over a dilution series of antibody stock solution. Curves shown are representative of 3 independent experiments.
TABLE 4. C3M Serum Levels in Patients with Montreal
class B1, B2, and B3 CD and HC
Groups of
Subjects N
C3M
Mean 6 SD
(ng/mL)
Lower & Upper
95% CI of Mean
P CD Patients
Versus HC
CD B1 50 14.87 6 5.36 13.35–16.40 ns
CD B2 41 11.60 6 4.53 10.17–13.03 ns
CD B3 22 23.29 6 12.50 17.74–28.83 0.0005
CD B3p 29 12.02 6 4.01 10.50–13.55 ns
HC 10 12.27 6 2.11 10.75–13.78
Statistical analysis was performed using one-way analysis of variance with Dunnett’s
Multiple Comparison Posttest.
ns, not signiﬁcant.
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FIGURE 4. Anti-MMP-9 antibody treatment reduces collagen deposition in intestinal grafts. Representative images of cross-sections of freshly isolated
small intestine (A–C) and of grafts explanted at day 14 after transplantation from mice treated with isotype control (D–F), with CALY-001 anti-MMP-9
antibody (G–I), or with AB-0046-h4 anti-MMP-9 antibody (K–M). Cross-sections were stained with Sirius red and observed under transmitted light
microscopy (A, B, D, E, G, H, K, L) and polarized light (C, F, I, M). Pictures B, C, E, F, H, I, L and M are ·10 magniﬁcations of sections A, D, G and K (merged
·5 magniﬁcation). (N) Collagen layer thickness was determined using Sirius red stained sections from freshly isolated small bowel at day 0 and from
grafts isolated 14 days after transplantation. Median, maximum, and minimum values are shown. One hundred ninety-four measures were performed
using 13 grafts for the day 0 group. At day 14 after transplantation, 157 measures were performed using 10 grafts for the CALY-001-treated group, 159
using 12 grafts for the isotype control–treated group, and 213 using 15 grafts for the AB-0046-h4–treated group. Statistical comparisons of anti-MMP-
9-treated groups versus the isotype control–treated group were performed using the one-way ANOVA with Dunnett’s multiple comparison posttest.
O, Hydroxyproline was determined using protein extracts of sections from freshly isolated small bowel resections (day 0, white bar) and from grafts
isolated 14 days after transplantation (black bars) from experiment 2. Hydroxyproline was quantiﬁed in 7 freshly isolated small bowel resections (day
0 group). At day 14 after transplantation, measures were performed using 6 grafts from the isotype control group and CALY-001- or AB-0046-h4–
treated group. Plots show group mean 6 SEM. Statistical comparison of groups was performed using one-way ANOVA with Dunn’s method. P value
designations are as follows: *, 0.05, **, 0.01, ***,0.001, ****, 0.0001, ns for nonspeciﬁc. ANOVA, analysis of variance.
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synthesized collagen (Fig. 4I, M). Quantitative analysis conﬁrmed
a signiﬁcantly thinner collagen layer in grafts from mice treated
with anti-MMP-9 antibodies compared with those treated with
isotype control (Fig. 4N). Quantiﬁcation of collagen-speciﬁc
amino acid hydroxyproline conﬁrmed lower collagen amounts
in grafts from mice treated with anti-MMP-9 antibodies compared
with those treated with isotype control (Fig. 4O). Collectively,
these results provide evidence that anti-MMP-9 antibodies can
control active intestinal ﬁbrotic process.
Expression of MMP-9 and TIMP-1 in Intestinal
Grafts is Not Affected by Anti-MMP-9
Antibody Treatment
Analysis of the mRNA expression of Mmp9 and its natural
inhibitor Timp1 was performed in grafts isolated 14 days after
transplantation. Transplants isolated from isotype control–treated
mice showed a signiﬁcant increase in Mmp9 and Timp1 mRNA
experssion levels related to Gapdh when compared with freshly
isolated small bowel resections (Fig. 5A, B). Interestingly, Mmp9
and Timp1 mRNA expression levels were similar in grafts from
isotype control- or from anti-MMP-9-treated groups (Fig. 5A, B).
MMP-9 protein expression was analyzed by IHC con-
ducted on serial sections of freshly isolated small bowel
resections or graft explanted at day 14 after transplantation
using anti-mouse MMP-9 antibody (Fig. 6A). Increased MMP-9
staining was detected in 14-day grafts (Fig. 6A, panels c–h)
when compared with freshly isolated small bowel (Fig. 6A,
panels a, b), whereas treatment with anti-MMP-9 antibodies
had no effect on MMP-9 protein expression levels (Fig. 6A,
panels e–h) when compared with isotype control–treated group
(Fig. 6A, panels c, d). Quantiﬁcation of MMP-9 positive cells
showed that their number was increased at day-14 after
transplantation, as compared with freshly isolated bowel resec-
tion (day 0) and remained unchanged regardless of the antibody
treatment (Fig. 6B).
MMP-9 Activity is Increased in Intestinal
Grafts and Modulated by Anti-MMP-9
Antibody Treatment
Gelatinase activity present in homogenates from freshly
isolated small bowel resections and from day-14 grafts explanted
from mice treated with either isotype control or anti-MMP-9
antibodies was assessed by zymography (Fig. 6C) and by ELISA
(Fig. 6D). It is worth noting that gelatin-based zymography uses
a polyacrylamide gel-based electrophoretic approach that disso-
ciates the complex made between antibody and antigen; thus,
antibody-mediated inhibition cannot be revealed by this method.
In contrast, the ELISA method preserves the immune complex
and enables the detection of antibody-mediated inhibition. More-
over, zymography provides semiquantitative information on total
MMP-9 amounts, with both pro-MMP9 and MMP-9 species
being revealed, whereas ELISA enables the quantiﬁcation of
active MMP-9. Very low MMP-9 amounts were found by zymog-
raphy in homogenates from all freshly isolated small bowel re-
sections (day 0), whereas all day-14 explants exhibited increased
total MMP-9 (Fig. 6C), which were mainly pro-MMP-9 species
(data not shown). Endowed with higher sensitivity (1 pg/mL), the
MMP-9 activity ELISA assay revealed that mature MMP-9 was
5.3-fold increased in grafts isolated from the isotype control group
compared with levels measured in freshly isolated small bowel
resections (Fig. 6D). Although not statistically signiﬁcant because
of the small sample number and the heterogeneity of data obtained
from the isotype control–treated group, the mean value of mature
MMP-9 was reduced by 2-fold in grafts from CALY-001-treated
FIGURE 5. Mmp9 and Timp1 mRNA expression in intestinal grafts. mRNA expression levels of Mmp9 (A) and of Timp1 (B) in freshly isolated bowel
resections (day 0) or in grafts isolated 14 days post implantation frommice treated either with isotype control or with anti-MMP-9 antibody (CALY-001
or AB-0046-h4). Results are reported as mean expression levels related to GAPDH 6 SEM. Number of grafts analyzed per group are indicated.
Statistical comparisons of means between each group and the isotype control–treated group were assessed by Kruskal–Wallis analysis. ns for not
signiﬁcant. P value designations are as follows: *, 0.05, **, 0.01, ***, 0.001, ****, 0.0001.
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mice when compared with grafts from the isotype control group. In
contrast, treatment by AB-0046-h4 failed to reduce active MMP-9
(the mean value 6 SEM ¼ 1.44 6 0.56 ng/mL; Fig. 6D). It is
worth noting that, unlike the CALY-001-treated group, the
AB-0046-h4–treated group exhibited high heterogeneity in
MMP-9 activity levels.
FIGURE 6. MMP-9 expression in intestinal grafts. A, IHC was conducted on serial sections of freshly isolated graft or graft explanted at day 14 after
transplantation using anti-mouse MMP-9 antibody (brown) and hematoxylin (blue), as counter staining. Staining was conducted on sections of
freshly isolated bowel resections (a, b) and of grafts isolated from mice treated with isotype control (c, d) or with anti-MMP-9 antibody (CALY-001
in e, f or AB-0046-h4 in g, h). IHC of a section from a non-treated animal (i) was the negative control. Negative control staining was performed on
section of graft explanted at day 14 after transplantation in absence of primary antibody. MMP-9 positive (MMP-9+) cells (yellow crosses in c–h)
were counted in areas of 50 mm in freshly isolated small bowel resections and in day 14 grafts. The ratios between the number of MMP-9+ cells
and the number of total cells (nuclei labelled with blue and yellow crosses) were reported in panel B. Numbers of areas analyzed are indicated in
graph columns. MMP-9 activity in intestinal grafts. Equal amounts of total protein extracted from homogenates of freshly isolated small bowel
resections (day 0) or of grafts isolated 14 days post implantation from mice treated either with isotype control or with anti-MMP-9 antibody (CALY-
001 or AB-0046-h4) were analyzed by zymography for total MMP-9 (C) and by ELISA for mature MMP-9 (D). Results are reported as mean MMP-9
activities 6 SEM. An n of 5 grafts per group were analyzed. Statistical comparisons between each group and the isotype control–treated group
were assessed using Mann–Whitney test. ns for not signiﬁcant, *for P , 0.05.
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Anti-MMP-9 Antibodies Co-localize with
Basement Membranes in Intestinal Grafts
The distribution of the injected antibodies after heterotopic
transplantation was investigated in histological cross-sections of
grafts. IHC with polyclonal rabbit anti-human IgG antibody revealed
intense staining in harvested grafts from mice treated with CALY-
001, AB-0046-h4, or isotype control (see Supplemental Fig., panels
A–I, Supplemental Digital Content, http://links.lww.com/IBD/B293)
as compared with the negative control (see Supplemental Fig., panel
K, Supplemental Digital Content, http://links.lww.com/IBD/B293).
Although epithelial structure was lost in heterotopic intestinal grafts,
both CALY-001 and AB-0046-h4 were also localized at sites where
the epithelial basement membrane of the former crypt area was ex-
pected (see Supplemental Fig., panels E and H, Supplemental Digital
Content, http://links.lww.com/IBD/B293). Both anti-MMP-9 antibod-
ies, CALY-001 and AB-0046-h4, co-localized with the vascular base-
ment membrane (see Supplemental Fig., panels F and I, Supplemental
Digital Content, http://links.lww.com/IBD/B293). Less human IgG
staining co-localized with basement membranes on treatment with
isotype control (see Supplemental Fig., panels B and C, Supple-
mental Digital Content, http://links.lww.com/IBD/B293). These re-
sults demonstrate an accumulation of anti-MMP-9 antibodies in
both epithelial and vascular basement membranes, probably result-
ing from the expression of MMP-9 at these locations.
Expression of TGF-b mRNA and TGF-b Protein
is Increased in Intestinal Grafts and Not
Altered by Anti-MMP-9 Antibody Treatment
Next we analyzed TGF-b mRNA and TGF-b protein
expression in intestinal transplants by real-time PCR and ELI-
SA. Tgfb1 mRNA expression was increased in day-14 grafts
compared with freshly isolated small bowel resections. How-
ever, it was equivalent in day-14 grafts from anti-MMP-9–trea-
ted groups compared with isotype control–treated animals (Fig.
7A). Similarly, TGF-b protein expression was increased in day-
14 grafts compared with freshly isolated small bowel resections,
but not modulated by anti-MMP-9 antibody treatment (Fig. 7B).
Modulations of the active fraction of TGF-b exhibited the same
pattern (data not shown). Together, these data suggesting that
the antiﬁbrotic effect observed in this model are not mediated by
control of TGF-b.
E-cadherin and a-SMA Expressions are
Modulated by Graft Transplantation, but Not
Affected by Anti-MMP-9 Treatment
We investigated the inﬂuence of anti-MMP-9 treatment on
E-cadherin and a-SMA expressions, both being hallmarks of
EMT, which play an important role in organ ﬁbrosis. IF with
anti-mouse E-cadherin antibody revealed intense staining in
intestinal epithelial cells of freshly isolated small intestinal
resection (Fig. 8A). In the isotype control–treated group, at
day 14 after transplantation, the loss of crypt structures and
luminal occlusion was complete and E-cadherin staining was
lost (Fig. 8B). As expected, labeling of freshly isolated small
intestinal resection with anti-mouse a-SMA antibody showed
minor staining, limited to subepithelial myoﬁbroblasts in the
crypts (Fig. 8E). a-SMA is a marker gained in myoﬁbroblasts
during intestinal ﬁbrosis. Expression of a-SMA in grafts at day
14 after transplantation was increased and rather patchy
(Fig. 8F). These 2 ﬁndings are in agreement with the expected
results on the induction of ﬁbrosis, i.e., decreased E-cadherin
and increased a-SMA expressions. However, treatment with
either anti-MMP-9 antibody did not trigger any signiﬁcant
change in expression of E-cadherin (Fig. 8C and D) or in
a-SMA (Fig. 8B, panel g and h). These results suggest that
the antiﬁbrotic effect observed is not mediated by control
of EMT.
FIGURE 7. TGF-b mRNA and protein expression in intestinal grafts.
mRNA and protein expression levels of TGF-b were quantiﬁed in
freshly isolated bowel resections (day 0) and in grafts isolated 14 days
post implantation from mice treated either with isotype control or
with anti-MMP-9 antibody (CALY-001 or AB-0046-h4). A, mRNA
expression levels are reported as mean expression levels related to
Gapdh 6 SEM. Numbers of grafts analyzed per group are indicated
within column of the graph. B, Total TGF-b levels are reported as mean
MMP-9 activities 6 SEM. An n of 5 grafts per group were analyzed.
Statistical comparisons of means between each group and the isotype
control–treated group were assessed by Kruskal–Wallis analysis. ns for
not signiﬁcant, *for P , 0.05.
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DISCUSSION
Based on the observed dysregulation of MMP-9 expression
and activity in the gut of active CD and UC, MMP-9 is considered
as a critical component of intestinal inﬂammation in IBD, but less
is known concerning the role of MMP-9 in penetrating or
stricturing CD. In this report, we describe a serological biomarker
of MMP-9 enzymatic activity, the C3M neopeptide generated by
MMP-9-mediated proteolytic cleavage of collagen III, whose
levels are signiﬁcantly elevated in penetrating CD when compared
with other CD patient subgroups. We propose that this new
biomarker could be used to identify patients who are more
susceptible to developing complex ﬁstulae and who could more
likely respond to anti-MMP-9 treatment. In a parallel approach, we
have generated an anti-MMP-9 antibody, CALY-001, and have
evaluated its efﬁcacy in a recently developed mouse model of
intestinal ﬁbrosis head to head with AB-0046-h4 used as a com-
parator. We show that inhibiting MMP-9 signiﬁcantly reduces
collagen deposition and intestinal tissue remodeling. This anti-
ﬁbrotic effect, associated with the anti-inﬂammatory effect of
MMP-9 inhibitor described in the DSS-colitis model by Marshall
and colleagues using AB-0046,32 supports the development of an
anti-MMP-9 antibody in patients with penetrating CD.
Patients with penetrating CD represent an unmet clinical
need, since none of the current therapies results in widespread
remission or in ﬁstulae closure. TNF antagonists are the most
effective drugs for penetrating CD, yet only one-third of the
FIGURE 8. Representative images of cross-sections of freshly isolated small intestine and of grafts explanted at day 14 after transplantation from
mice treated with isotype control (B and F), with anti-MMP-9 antibody CALY-001 (C and G), or AB-0046-h4 (D and H). IF staining of E-cadherin (red)
and of DAPI (blue) are shown in pictures A–D. IF staining of a-SMA (red) and of DAPI (blue) are shown in pictures E–H. (I) Negative control, graft
explanted at day 14 after transplantation stained in absence of primary antibody. The original ·65 magniﬁcation was 2-fold enlarged with the LAS
AF software. Each image is representative for 5 samples investigated. Dashed line, crypt cut along the long axis. Arrow, erythrocytes.
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patients will respond to anti-TNF antibody treatments and another
third will lose response during the ﬁrst year of treatment because of
intolerance or appearance of antidrug antibodies.37,38 This results in
a cumulative risk of intestinal resection of 70% during the ﬁrst 15
years after diagnosis. We suggest that an anti-MMP-9 antibody has
advantages over current treatment options for penetrating CD
because simultaneously targeting inﬂammation, tissue destruction,
and ﬁbrosis that drive ﬁstula formation may lead to superior efﬁ-
cacy than that achieved with classical immunosuppressive agents.
The implication of MMP-9 as a primary disease driver in IBD is
unequivocal. Several reports describe upregulation of MMP-9
expression and activity in inﬂamed mucosa or serum of patients
with IBD39,40 and recent safety and efﬁcacy data of Gilead Scien-
ces’s anti-MMP-9 antibody, GS-5745, in a multicenter, double-
blind, phase Ib study in patients with moderate to severe UC
support the therapeutic promise of an anti-MMP-9 antibody.40a
Enhanced MMP-9 transcripts and protein levels were
described in lamina propria mononuclear cells, granulocytes,
and giant cells in CD ﬁstula specimens with acute inﬂammation
and granulation tissue. Fistulae were also shown to express active
MMP-9,13,41,42 indicating that MMP-9 may contribute to ﬁstula
formation. Our IHC analysis of ﬁstula specimens shows that
MMP-9 expression was closely associated with epithelial and
inﬂammatory cells adjacent to the ﬁstula tracks, which is in agree-
ment with our previous ﬁnding where we could show increased
MMP-9 protein expression in colonic lamina propria ﬁbroblasts
from ﬁstula patients compared with control ﬁbroblasts.43 These
observations indicate the presence of substantial amounts of
MMP-9 associated with ﬁstulae that trigger excessive production
and release of tissue-speciﬁc protein fragments, locally as well as
in the circulation. Proteolytic degradation fragments measured in
serum have received increased attention because of their diagnos-
tic and prognostic potential in diseases. For example, in the phase
III LITHE biomarker study in rheumatoid arthritis, it was possi-
ble, using the C2M and C3M biomarkers of joint tissue remodel-
ing, to identify the proﬁles of responders and nonresponders to the
anti-IL-6R antibody tocilizumab.44 Recently, Mortensen and col-
leagues reported that the biomarkers VICM (degradation fragment
of citrullinated protein vimentin), C3M, C1M, and C4M are
potential biomarkers that differentiate IBD from non-IBD pa-
tients, whereas both VICM and C3M may also be biomarkers that
differentiate patients with CD from patients with UC.45 Mortensen
and colleagues also found that BGM is highly elevated in UC
compared with CD. In this study, we investigated the proﬁle of
speciﬁc MMP-9-generated protein products in serum from CD
patients with inﬂammatory, ﬁbrostenotic or penetrating phenotype
to assess whether serum levels of speciﬁc MMP-9 degradation
products reﬂect these different pathogenic features of CD. Among
the 5 peptides quantiﬁed, C1M, C3M, C6M, LAM, and BGM,
only C3M, which results from MMP-9-speciﬁc degradation of
type III collagen, was signiﬁcantly elevated in patients with pen-
etrating CD when compared with HC and with other CD sub-
groups, indicating that C3M has the potential to be a biomarker of
MMP-9 activity associated with complex ﬁstulae. In our study,
mean value of C3M serum levels in CD B3 patients and HC were
lower than values reported by Mortensen and colleagues in pa-
tients with CD and UC and in HC. It is worth noting that their data
were obtained from 2 independent cohorts of patients with CD, in
which only 7% and 10% of patients had penetrating disease. The
heterogeneity within the patient cohorts may account for the dif-
ference observed since C3M levels were assessed using identical
ELISA technology in both studies. It also worth mentioning that
Mortensen and colleagues reported the highest levels of C3M in
patients with UC, suggesting that similar MMP-9-mediated ECM
remodeling processes take place in UC and in the CD B3 group.
In contrast, serum levels of another MMP-9-speciﬁc neo-
epitope, BGM, were similar in patients with penetrating CD when
compared with other CD patient groups. BGM peptide is derived
from biglycan (BGN), which is a secreted proteoglycan belonging
to the family of small leucine-rich proteoglycans present in sites
affected by ﬁbrosis and which controls lateral assembly of
collagen ﬁbers.46,47 The fact that circulating levels of C3M, but
not of BGM, were found associated with penetrating CD indicates
that MMP-9 activity and the presence of collagen type III provide
a unique combination relevant for the CD B3 patient group.
Indeed, quantiﬁcation of circulating C3M levels seems to be
a powerful indicator of ﬁstulae since past attempts to reveal a rela-
tionship of MMP-9 activity in inﬂamed CD tissue with the co-
presence of ﬁbrosis or ﬁstula by gelatin zymography failed.41
Similarly, collagen contents in resected strictured intestine of pa-
tients with CD were found similar, regardless of the presence of
ﬁstula.48 A systemic C3M biomarker has the potential to serve as
marker for the development of ﬁstula that cannot be easily iden-
tiﬁed clinically. These ﬁndings warrant further studies aiming at
exploring the potential use of C3M to assess severity of penetrat-
ing CD and efﬁcacy of MMP-9 inhibitor.
The anti-ﬁbrotic effect of anti-MMP-9 antibodies was
successfully characterized in our model of intestinal ﬁbrosis. A
model recapitulating the pathogenesis of intestinal ﬁstula does not
exist. Rat models in which ﬁstula are surgically created have been
used to assess repair agents such as chitosan hydrogel,49 stable
gastric pentadecapeptide BPC 15750 or stem cell therapy.51 Unfor-
tunately, these models are not suitable for testing agents having
the potential to control cellular and molecular processes leading to
ﬁstula development as those are bypassed in the surgical models.
The association of aberrant chronic inﬂammation and repair pro-
cesses resulting in collagenous tissue has been linked with ﬁstula
development. Therefore, studies using pharmacological agents in
intestinal inﬂammatory models and in intestinal ﬁbrosis models
would suggest that they could show amelioration or prevention
of ﬁstula development. Since both anti-MMP-9 antibodies,
AB-0046-h432 and CALY-001 (data not shown) were shown to
reduce disease severity in a DSS-induced mouse model of intes-
tinal inﬂammation, it was logical to assess the antiﬁbrotic activity
of our anti-MMP-9 antibody in a model of intestinal ﬁbrosis,
using AB-0046-h4 as a reference compound. Heterotopic trans-
plantation of small bowel resections in mice was followed by
ﬁbrosis of the intestinal wall. Sirius Red staining conﬁrmed
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a signiﬁcant increase of collagen layer thickness in day-14 trans-
plants and revealed a diffused network of ﬁbrils in the obliterated
lumen. Reverse transcription polymerase chain reaction, IHC, and
zymography experiments showed that MMP-9 gene and protein
expression as well as MMP-9 activity were signiﬁcantly increased
in day-14 transplants compared with freshly isolated small bowel
resections. Therapeutic dosing of 2 nonrelated anti-MMP-9 anti-
bodies in this model showed that inhibiting MMP-9 signiﬁcantly
restrains ﬁbrogenesis, as revealed by a signiﬁcant decrease of the
thickness of the collagen layer and hydroxyproline levels in day-
14 grafts compared with grafts isolated from isotype control–treated
mice. The fact that both antibodies used in this study inhibit
MMP-9 with a different mechanism of action strengthens these
results. CALY-001 is an inhibitor of MMP-9 enzymatic activity,
whereas AB-0046-h4 is an inhibitor of pro-MMP-9 activation
leading to decreased MMP-9 activity. Moreover, we observed that
anti-MMP-9 antibodies co-localized with epithelial and vascular
basement membranes in day-14 grafts, proving that both blocking
antibodies have reached the site where their target exerts its enzy-
matic activity. Using an ELISA assay, we observed a trend of
anti-MMP-9 antibody–mediated inhibition of MMP-9 activity in
grafts of mice treated with CALY-001. However, we could not
obtain statistical signiﬁcant differences in activity means between
CALY-001 and isotype control–treated mice, probably due to the
small number of mice tested and to the heterogeneity in data
obtained in the isotype control group. Serum levels of C3M were
very low in all groups of mice, certainly because ﬁbrosis is limited
to the intestinal grafts in this model and C3M locally produced is
diluted in the blood.
Studies using either Mmp9-deﬁcient mice in a model of
obstructive nephropathy52 or MMP-9 neutralizing antibody in
murine unilateral ureteral obstruction model have shown a reduction
of kidney ﬁbrosis53 mediated by (1) inhibition of tubular cell EMT,
an major source of myoﬁbroblast in kidney ﬁbrosis; (2) inﬁltration
of interstitial macrophage, a major source of MMPs and proﬁbrotic
cytokines. In addition, MMP-9 itself has been shown to induce the
entire course of renal tubular cell EMT through cleavage of colla-
gen and laminin and disruption of E-cadherin/b-catenin–mediated
cell-to-cell adhesion complex,11,54 leading to loss of tubular base-
ment membrane integrity. EMT is characterized by loss of epithe-
lial markers such as E-cadherin and cytokeratin, and by nuclear
translocation of b-catenin accompanied by de novo expression of
mesenchymal markers typically a-SMA. A number of EMT char-
acteristic events were documented in and around ﬁstula tracts sup-
porting a role for EMT in the pathogenesis of CD-associated
ﬁstulae.55 It was logical to speculate that similar mechanisms
may account for the intestinal ﬁbrosis observed in the heterotopic
intestinal transplant model. Our results showed that collagen depo-
sition in the day-14 grafts was correlated with loss of E-cadherin
and induction of a-SMA expression. However, the therapeutic
effect observed with anti-MMP-9 antibodies was not correlated
neither with restored E-cadherin nor decreased a-SMA expression
in intestinal grafts indicating that ﬁbrosis in these grafts was con-
trolled by another mechanism. TGF-b is known to play a crucial
role in tissue remodeling and inﬂammation in the gut. TGF-b pro-
motes collagen production by smooth muscle cells isolated from
CD tissue56 and inhibits intestinal epithelial cell proliferation, a pro-
cess that may inhibit re-epithelialization after surface injury.57 In
addition, TGF-b is activated by MMP-9-mediated proteolytic
cleavage of latent TGF-b.58 We therefore explored whether the
antiﬁbrotic activity of the anti-MMP-9 antibody treatment was
associated with a decreased TGF-b production or activity. We
observed that total and active TGF-b levels were increased in
day-14 grafts, but these levels were not altered by anti-MMP-9
antibody treatments. Using the same mouse model of intestinal
ﬁbrosis, we found that treatment with pirfenidone led to the
decrease of collagen deposition in grafts which correlated with
a signiﬁcantly reduction of TGF-b expression.25 Grafts from mice
treated with pirfenidone showed a signiﬁcant decrease in Acta2
(a-SMA) and Mmp9 mRNA expression compared with vehicle,
suggesting that the antiﬁbrotic effect of pirfenidone observed in
this model was mediated by altered MMP-9 expression. The fact
that, in this study, we could not correlate the reduction in collagen
deposition in day-14 grafts mediated by 2 independent anti-MMP-9
antibodies with a local molecular process suggests that graft-
associated ﬁbrosis might have been controlled by a systemic
response. Although we could not reveal the mechanism by which
anti-MMP-9 antibodies have controlled the collagen deposition in
day-14 intestinal grafts, our results warrant further studies in other
models of intestinal ﬁbrosis.
In this report, we demonstrate the association between an
MMP-9 degraded type III collagen fragment C3M and penetrating
CD indicating that C3M has the potential to be a marker of the
development of ﬁstulae. In addition, we demonstrated that
antibody-mediated inhibition of MMP-9 reduced collagen depo-
sition in grafts from a heterotopic intestinal transplant model,
suggesting that inhibition of MMP-9-mediated proteolysis could
be an effective means of dampening ﬁbrosis that contributes to
ﬁstula development.
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